S-1 · primary offering
Issued 2024
Proposed maximum
Shares registered
- Filed
- Effective
APUS$2.82-2.42%
Apimeds Pharmaceuticals US, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: NYSE
Mkt Cap:$4.35M
Float & O/S:
Inst Own:
DilutionScan read 17 of Apimeds Pharmaceuticals US, Inc.'s SEC filings and found 3 warrant series, 4 convertibles, 1 S-1 registration and 1 completed offering on file for APUS. The latest dilution event on file is an offering on Dec 8, 2025. Analysis updated Sep 24, 2026.
Signal8 Summary
APUS
Going-concern warning, default on debt
Snapshot
APUS is a clinical-stage drug developer with zero revenue that has effectively become a crypto-and-blockchain holding company after a 2025 merger.
What's Happening Right Now
- : Interim CFO Erick Frim resigned September 29, 2026, and Eric Sherb was appointed CFO effective October 1, 2026 on a $60,000 base salary.
- : Subsidiary MindWave signed two 12-month blockchain agreements (AQUAEChain and FlashChain) paid mostly in equity and tokens with undisclosed dollar value.
- : APUS completed a 1-for-10 reverse split effective July 24, 2026, cutting shares outstanding from about 15.1M to 1.5M.
- : APUS gained additional Apitox-related rights, including a 25% royalty on future U.S. commercialization proceeds, via an assignment from FreeT Inc.
- : APUS reported a $55.2M six-month net loss with only $278K cash, disclosed going-concern doubt, and faces default on a $10.9M convertible note plus $5M of unpaid matured notes; it must regain NYSE American compliance by October 15, 2026 or risk delisting.
- : Raised $10.00M in gross proceeds through a private placement (PIPE), and a $10.90M convertible note.
- : Issued warrants over 75K shares.
- : Issued warrants over 20K shares.
Raise routes on file: no active ATM, effective shelf, S-1 or equity line in the filings read · latest dilution event 330 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Dec 8, 2025 · Offering
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Completed
IPO Representative Warrants ( issued May 12, 2025)
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Series A Convertible Preferred Stock
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
PIPE
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your APUS trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
